Scientific Validity and Fair Subject Selection: An Empirical Analysis of Recruitment Practices in Clinical Trials

Dr Gagan Gunjan[1*], Dr. Santhosha Kulal[2], Manoj Ghosh[3], Dr Sukanta Bandyopadhyay[4]

[1*]*Assistant Professor, Gen Medicine, Rajendra Institute of Medical Sciences, Ranchi. Jharkhand gagangunjan@rediffmail.com*
[2]*Assistant Professor, Department of Radiation Oncology, Sri Devaraj Urs Academy of Higher Education and Research, Sri Devaraj Urs Medical College, Tamaka, Kolar, Karnataka India santhoshak168@gmail.com 0000-0002-9014-642X*
[3]*Assistant Professor, Department of Hospital Management, NSHM Knowledge Campus Durgapur 0000-0001-9010-4636, mg.prahlad@yahoo.in*
[4]*Associate Professor, Dept of Biochemistry. Rama Medical College Hospital & Research Centre, Mandhana, Kanpur (U.P) -- 209 217. India. sukantoaxum@gmail.com*

KEYWORDS

Clinical trials, Recruitment practices, Diversity, Institutional policies, Scientific validity, Racial disparities, Community engagement

ABSTRACT

This study investigates the relationship between scientific validity and fair subject selection in clinical trials, focusing on recruitment practices. By analyzing 200 clinical trials across oncology, cardiology, and neurology, this research identifies key barriers to diversity and assesses the effectiveness of institutional policies in promoting equitable recruitment. The findings reveal that despite efforts to improve inclusivity, demographic disparities persist, particularly in terms of racial and ethnic representation. Recruitment barriers, including logistical challenges, mistrust among minority groups, and insufficient outreach resources, are prevalent, with oncology trials exhibiting the most significant issues related to minority participation. Additionally, the study highlights that stronger Institutional Review Board (IRB) policies with enforced diversity guidelines lead to higher minority representation in trials. Through a mixed-methods approach, combining systematic trial reviews, surveys of recruitment personnel, and institutional policy assessments, the study emphasizes the importance of community engagement and culturally competent recruitment strategies. The research suggests that while progress has been made, greater transparency, targeted outreach, and mandatory diversity tracking are necessary to achieve equitable and scientifically valid clinical trial outcomes. The study concludes with recommendations for future research to explore technological innovations and broader therapeutic areas, offering potential solutions for overcoming the barriers to diversity in clinical trials.

1. Introduction

The ethical conduct of clinical trials is foundational to advancing medical knowledge and improving patient outcomes. One of the core principles guiding ethical clinical research is fair subject selection, which entails that participants should be chosen based on scientific objectives rather than arbitrary or unjustifiable criteria (Emanuel et al., 2000). Proper recruitment practices ensure that trials are not only scientifically valid but also equitable, offering potential benefits across populations without unnecessary risk imposition or exploitation (Emanuel et al., 2004). Given the significant ethical and scientific implications, recruitment practices are critical to the design and success of clinical trials. Historically, recruitment methodologies have often been influenced by various socio-economic, racial, and demographic factors, sometimes leading to ethical challenges and impacting the validity of research findings (Kobayashi et al., 2019). Ensuring that clinical trials recruit a representative and fair sample of participants is, therefore, not just an ethical imperative but a scientific necessity to achieve valid, generalizable results.

Scientific validity in clinical trials is directly linked to the representativeness and diversity of study populations. A study that fails to include a broad spectrum of participants may yield findings that are less applicable to the general population, potentially overlooking important variations in treatment effects among different demographic groups (George et al., 2014). The selection process, therefore, must be methodically planned to ensure a comprehensive inclusion of diverse populations. However, achieving fair subject selection often faces challenges, including implicit biases in recruitment, logistical constraints, and a potential lack of awareness among underrepresented communities (Hussain-Gambles et al., 2004; Salmanu et al., 2023). Researchers must navigate these obstacles carefully to balance scientific rigor with ethical responsibility.

One of the primary challenges in clinical trial recruitment is overcoming the underrepresentation of certain demographics, particularly racial and ethnic minorities (George et al., 2014). This underrepresentation can skew trial outcomes and, by extension, treatment efficacy, as the biological and socio-environmental differences among populations can influence health outcomes significantly. For instance, a systematic review of recruitment practices revealed that minority populations often face structural barriers to participation, including limited access to trial sites, cultural distrust, and socioeconomic challenges (Shavers et al., 2001). Such obstacles not only limit the inclusiveness of clinical trials but also call into question the generalizability of findings. When studies predominantly involve participants from homogenous backgrounds, the results may lack relevance for diverse populations, compromising the applicability of new treatments and therapies.

The recruitment process is also deeply intertwined with the ethical concept of autonomy, as potential participants must be adequately informed and freely consent to join a trial (Appelbaum et al., 2009). The principle of autonomy demands that individuals make informed decisions based on a clear understanding of the study, its potential risks, and its benefits. In practice, however, recruitment methods may sometimes fail to provide participants with sufficient information, inadvertently leading to coercion or undue influence (Lipkus et al., 2009). These ethical challenges underscore the need for transparency and standardized recruitment protocols that respect participant's autonomy and promote informed consent.

A further dimension of fair subject selection pertains to the equitable distribution of risks and benefits among participants. Historically, there have been instances where vulnerable populations, such as economically disadvantaged individuals, were disproportionately enrolled in high-risk studies due to a lack of alternative healthcare options (Wendler et al., 2006). Such practices have raised ethical concerns about exploitation and justice, as they burden certain groups with greater risks while potentially benefiting other segments of society disproportionately. To counter this, guidelines like the Belmont Report emphasize that no group should bear an undue burden of risk, and the benefits of research should be equitably shared among all populations (Department of Health, Education, and Welfare & National Commission for the Protection of Human Subjects of Biomedical and Behavioral Research, 2014).

The importance of ensuring scientific validity and fair subject selection is further highlighted in the context of phase III clinical trials, where the results are expected to inform clinical practice broadly (Duma et al., 2018). Phase III trials typically involve large sample sizes to evaluate the efficacy and safety of new interventions in diverse populations, necessitating rigorous recruitment strategies to include participants across different demographic and socio-economic backgrounds (Unger et al., 2016). Given the implications of these trials for public health, a lack of diversity in participant selection not only limits scientific validity but can also lead to significant health disparities. For instance, a review of cancer clinical trials indicated that minority populations are underrepresented in studies despite bearing a higher burden of disease, which could lead to inequities in cancer treatment access and outcomes (Unger et al., 2016).

To address these challenges, various frameworks and ethical guidelines have been developed to guide recruitment practices in clinical trials. The Common Rule and the Declaration of Helsinki are among the most influential documents that set standards for fair recruitment, advocating for transparent, non-coercive practices and the equitable inclusion of diverse populations (World Medical Association, 2013; National Center for Health Statistics [NCHS], 2019). These guidelines

encourage researchers to actively seek diverse participants and remove barriers to recruitment. For example, outreach programs and community partnerships have proven effective in fostering trust and enhancing participation among underrepresented populations (Brown et al., 2012).

In recent years, there has also been an increased emphasis on the use of community engagement strategies to improve recruitment practices. Community engagement fosters trust, cultural competency, and understanding between researchers and participants, leading to higher enrollment rates and retention among minority groups (George et al., 2014). This approach recognizes the importance of addressing historical injustices and mistrust that may deter certain groups from participating in clinical trials. By incorporating community perspectives into the research process, trials can be better tailored to meet the needs of diverse populations and achieve more equitable outcomes (Fisher et al., 2011; Rosenberger & Lachin, 2015).

In conclusion, scientific validity and fair subject selection are interdependent pillars of ethical clinical research. Ensuring that recruitment practices are fair and scientifically sound not only advances public trust in research but also promotes the generalizability and applicability of study findings. As clinical trials continue to evolve, researchers must adopt inclusive recruitment strategies and uphold ethical standards to serve the diverse needs of global populations. This study aims to empirically analyze current recruitment practices in clinical trials, evaluating their alignment with the principles of scientific validity and fair subject selection. Through this analysis, the research seeks to contribute to a deeper understanding of how ethical and scientific standards in participant recruitment can be upheld in practice, ensuring that clinical trials benefit all segments of society equitably.

2. Methodology

Study Design

This study employed a cross-sectional, mixed-methods design to sample and describe clinical trial recruitment practices and the demographic characteristics of recruited participants. Data were collected from three sources including A review of clinical trial databases, questionnaires completed by personnel involved in recruitment, as well as analysis of policies governing IRBs. Data from the trials that were carried out between 2015 and 2023 in high-demand specializations such as oncology, cardiology, and neurology were used. The systematic review focused on the demographics of the participants involved in the intervention and the survey involved an evaluation of the recruitment methods adopted and the challenges encountered.

Data Collection Systematic

Review of Clinical Trials

Randomized and controlled trials were identified from Clinical Trials, PubMed, and the World Health Organisation International Clinical Trials Registry. The criteria for inclusion were used including the recruitment information that was available to the public, information on participant characteristics, trial sample size, inclusion/exclusion criteria, and diversity. Trials were divided according to the therapeutic area and the demographic distribution of the participants as well as their gender and race was also examined to determine the diversity across different fields of clinical research.

Survey of Recruitment Personnel

An online questionnaire was distributed to 50 clinical trial recruitment staff in a range of research organizations to investigate the recruitment process, issues, and obstacles to diversity. The survey was also comprised of closed and open-ended questions to measure quantitative and qualitative data regarding different strategies and challenges of the recruitment process and the level of success in the enrollment of a diverse population. Postcard responses were examined to discover the nature of current recruitment processes and difficulties, as well as patterns between particular recruitment techniques and diverse Clinical Trial enrolment results.

Institutional Policy Analysis

The policies of 25 IRBs were assessed to identify their stance and actions regarding diversity and inclusion. The policy elements examined were related to the diversity requirement of the workforce, community engagement initiatives, and reporting of workforce data. The applicability and enforcement of these guidelines were then studied to gauge their effectiveness on diversity results in clinical trials. The comparison was made between institutions that have strict diversity policies in place and institutions that do not have very rigorous policiesto determine how well the policies increased the diversity of the participants.

Data Analysis

Quantitative Analysis

Mean, mode, and frequency were used to analyze participant's characteristics and survey responses. Chi-square tests and logistic regression analyses were done to examine the relationship between recruitment practices, and participant diversity. Thus, these statistical methods assisted in describing the recruitment strategies and possible relationships between recruitment and clinical trial participant's characteristics.

Qualitative Analysis

Free-text responses provided in the surveys were coded and categorized content-analysis-wiseto determine the main recruitment challenges and enablers. This has been a qualitative study and has yielded information that helped explain the problems and solutions affecting diversity in clinical trial participants.

Policy Impact Assessment

Recruitment data from trials conducted under the supervision of IRBs with more rigid diversity policies were then compared with data from less stringent IRBs to examine how diversity enforcement affects recruitment and participant characteristics.

3. Results

Participant Demographics in Clinical Trials

In total, the characteristics of 200 trials have been analyzed, including a total of 90 oncological, 70 cardiological, and 40 neurological trials with an overall enrolment of approximately 12,000 participants. Thus, there were differences across therapeutic areas, especially in terms of race/ethnicity distribution. Details are mentioned in Table 1 where it was noted that oncology trials had the lowest percentage of male subjects, at 52%, and possibly the most balanced by age, except for cardiology trials that had a mean age of 64 ± 10 and a percentage of 22% for the minority. The number of trials available in neurology was moderate, ethnicity was also moderate at 25%.

Table 1: Participant Demographics by Therapeutic Area

Therapeutic Area	Total Participants	Mean Age (± SD)	% Female	% Minority
Oncology	5,000	57 ± 13	52%	28%
Cardiology	4,000	64 ± 10	45%	22%
Neurology	3,000	50 ± 15	49%	25%



Figure 1: Age and Gender Distribution by Therapeutic Area

Figure 1 illustrates the age and gender distribution across three therapeutic areas which are the fields of oncology, cardiology, and neurology. That means that there is a quite fairly equal representation of both genders in oncology (52% female, 48% male) and neurology (49% female, 51% male). But cardiology trials are more masculine studies with 55% of white males and only 45% of females. The plot reveals the demographic differentiation within these therapeutic areas.

Recruitment Practices and Barriers

The recruiting personnel survey showed that diversity faced several issues such as practical issues (50%), lack of trust from the minority groups (40%), and lack of outreach instruments (35%). Facilities that adopted external community engagement programs and cultural competencies training indicated a twenty percent enhancement of diversity in the recruitment process. Remarkably, clear sex and age differences were observed across all therapeutic areas, as presented in the Table 2 depicting participant characteristics. Such results highlight the importance of approaches to tackle the difficulties in recruitment of participants and improve diversity in trials.

Table 2: Recruitment Barriers Reported by Survey Respondents

Recruitment Barrier	Percentage of Respondents Reporting
Logistical constraints	50%
Mistrust among minority populations	40%
Limited outreach resources	35%
Lack of inclusivity training	25%

Figure 2 shows the distribution of recruitment barriers by the therapeutic area. Minority populations have the highest levels of mistrust in oncology trials at 60% and the second most at 45% for logistical hurdles. Other therapy specialities also face barriers that are cardiology and neurology trials, for example, most frequently cite logistical and lack of outreach resources. These results indicate the specific issues in the respective therapeutic areas concerning a diverse recruitment.



Figure 2: Recruitment Barriers by Therapeutic Area

Impact of IRB Policy on Recruitment Diversity

The policy review also revealed that of the IRBs that were sampled, 60% encouraged diversified recruitment strategies, but only 30% required diversity tracking. Universities with specific diversity policies for recruitment and retention had recorded increased minority status than institutions with no such policies, suggesting that the guidelines make a difference in equitable recruitment. Table 3 shows that 60% of IRBs approved diversity recruitment, 30% actually employ enforcement mechanisms, which can indicate the reasons for discrepancies between policy and trial diversity.

Table 3: IRB Policy Attributes on Diversity Monitoring

IRB Policy Attribute	Percentage of IRBs Implementing
Diversity recruitment recommendations	60%
Diversity monitoring enforcement	30%
Community engagement guidelines	40%
Comprehensive demographic data reporting	35%



Figure 3: Minority Representation in Trials by IRB Policy Enforcement

Figure 3 depicts the effect of enforcement of the IRB policy in the participation of the minorities in clinical trials. In trials that are approved by IRBs that have mandatory diversity policies in place, representation of minorities was found to be much better at 40% compared to only 22% in trials that underwent IRBs without such enforced policies. The data supports the evidence that high stringency of diversity policies increases recruitment equity across different therapeutic areas.

4. Discussion

This research contributes to the existing knowledge of the best practices for recruitment in clinical trials, with emphasis on the ethical and scientific aspects of subject inclusion. A few challenges associated with the recruitment of minorities in clinical trials are among the focus of this study in oncology, cardiology, and neurology. From this participant demographic data, method of recruitment, and IRB regulations, this paper shows how difficult it is for clinical researchers to achieve fair and scientifically proper recruitment. The outcomes also provide evidence of the high efficacy of diversity-related measures and community involvement in promoting participant inclusion. These results align with prior work, but they also provide new insights into how recruitment practices affect trial outcomes themselves.

One of the important results of this work was the persistence of the problem of racial minority enrolment in clinical trials. While minorities participate in neurology (25%) and oncology (28%) trials to a greater extent than cardiology (22%), the numbers still do not reflect representation in the general population; they further increase in trials for chronic diseases that severely affect minorities, including cancer, cardiovascular diseases, and neurological disorders (Unger et al., 2016). This underrepresentation is not only unethical since it violates the basic ethical principle of fairness in subject selection but is also scientifically problematic as the results of trials cannot be generalized to and therefore are not useful for, diverse populations (Esnaola and Ford, 2012; Faust et al., 2021). It has been observed that there wasa disproportionate enrolment of White people, and middle-aged or elder adults in trials and the results obtained may not reflect well on the effects of treatment especially in underrepresented groups (George et al., 2014).

Recruitment barriers and their influence on participant diversity were also highlighted by this study; the main challenges were; logistical barriers (50%), lack of trust from minorities (40%), and limited outreach resources (35%). These observations are not dissimilar from earlier studies that have reported on the many challenges that racial/ethnic minorities have in accessing and enrolling in clinical trials; these include a perceived lack of trust resulting from historical prejudice and socioeconomic factors (Bharmjeet & Das, 2023). The absence of culturally sound fliers and other recruitment materials as well as the lack of culturally appropriate methods of reaching out to underrepresented populations play a big role in these issues (Kelsey et al., 2022). This study also further supports the need to engage the community to increase diversity in recruitment practices. For example, those organizationsthat had implemented external community engagement programs and cultural competency training programs indicated enhanced participant diversity by 20%.

The role of IRB policies in influencing recruitment practices also came out clearly in this study. In this study, sixty percent of the IRBs reviewed called for diversity recruitment policies, while only thirty percent mandated diversity implementation. This makes many institutions have policies of diversity in clinical trials, but a lack of enforcement measures may reduce the impact of the policies (Singh et al., 2024). The findings in this present study also support the fact that diversity policies are positively associated with improvements in minority participation in clinical trials. In particular, the trials conducted under IRBs with mandatory diversity policies had 40% minorities while those run under IRBs without such policies involved 22% minorities. These results stress that not only the standard of diversity rules should be set for the organizations, but also checked for effectiveness in terms of changing the recruiter’s behavior.

However, it is crucial to understand the results of the recruitment factors and characteristics of the participants for clinical trial design. It remains important and relevant to take measures that a trial be designed with an appropriate representation of different groups of patients. According to a previous study, for clinical practice, phase III trials need to include participants from a diverse

population background so that the findings of the study can be representative of the larger population (Curtis et al., 2017). This is especially relevant in an area of medicine like oncology in which the disparities in both incidence and mortality of cancer among minorities are known.

Besides, the difficulties encountered in the process of recruitment emphasize the importance of constant work on the increase of clinical trial diversity. So, it is evident that recruitment strategies need not be confined to sourcing participants from a wider population. It requires them to respond to the systemic, societal, and cultural issues that have rendered some participants marginal to research. For example, the suspicion that is apparent in ongoing relations between minorities and health systems, especially in oncological trials, is best addressed directly (Borno et al., 2021). To encourage participation in research, scholars have to ensure the participant's and other stakeholder's willingness to engage in a research process, which can be achieved through the following ways all these efforts are important in a bid to make the clinical trial more rigorous, fair, and scientific

Based on the conclusion of this study, recommendations can be made to enhance the recruitment process of clinical trials. First, there is a need to enhance the cultural sensitivity of recruitment procedures that will suit the cultural diversity of the targeted groups. This includes the development of appropriate information that people can understand and take home. Second, there should be strict adherence to diversity recruitment policies whereby institutions should hire agencies that ensure that the minority gets included in the clinical trials. Third, specific and cumulative community injustice should be addressed in research to overcome past mistreatment and establish rapport.

Conclusion and Future Scope

This study highlights the critical relationship between scientific validity and fair subject selection in clinical trials, emphasizing the importance of recruitment practices that promote both inclusivity and generalizability. The findings demonstrate that despite advancements in recruitment strategies, significant barriers remain in ensuring equitable participant representation, particularly among underrepresented racial, ethnic, and socio-economic groups. Variations in recruitment practices across therapeutic areas—oncology, cardiology, and neurology—underscore the need for tailored approaches that address unique demographic challenges. Importantly, the data suggest that institutional policies and community engagement efforts have a substantial impact on improving diversity, pointing to the need for more rigorous enforcement of diversity recruitment standards.

The study also sheds light on the persistent logistical, cultural, and trust-related barriers to diversity in clinical trials. As such, while progress has been made, there remains a need for increased transparency, better outreach strategies, and comprehensive diversity tracking. The evidence that stronger Institutional Review Board (IRB) policies positively correlate with better diversity outcomes calls for the wider adoption of such policies in clinical research institutions.

Future research should focus on refining recruitment strategies and overcoming logistical challenges, particularly for minority populations. Expanding the scope of the study to include a broader range of therapeutic areas and longitudinal data will help further assess the long-term impact of inclusive recruitment practices. Additionally, exploring the role of technological innovations in enhancing participant diversity, such as digital health platforms and mobile recruitment tools, could offer valuable insights into addressing these challenges more effectively.

Reference

[1] Appelbaum, P. S., Lidz, C. W., & Klitzman, R. (2009). Voluntariness of consent to research: a conceptual model. *The Hastings Center report*, *39*(1), 30–39. https://doi.org/10.1353/hcr.0.0103

[2] Bharmjeet, Das A. Racial disparities in cancer care, an eyeopener for developing better global cancer management strategies. Cancer Rep (Hoboken). 2023 Sep;6 Suppl 1(Suppl 1):e1807. doi: 10.1002/cnr2.1807. Epub 2023 Mar 27. PMID: 36971312; PMCID: PMC10440846.

[3] Borno, H. T., Lin, T. K., Zhang, S., Skafel, A., Lalanne, A., Dornsife, D., ... & Rhoads, K. F. (2021). Accelerating cancer clinical trial recruitment through a financial reimbursement program integrated with patient navigation: an interrupted time series analysis. *Journal of Cancer Policy*, *30*, 100305.

[4] Brown SD, Lee K, Schoffman DE, King AC, Crawley LM, Kiernan M. Minority recruitment into clinical trials: experimental findings and practical implications. Contemp Clin Trials. 2012 Jul;33(4):620-3. doi: 10.1016/j.cct.2012.03.003. Epub 2012 Mar 16. PMID: 22449836; PMCID: PMC3361553.

[5] Curtis, K., Fry, M., Shaban, R. Z., & Considine, J. (2017). Translating research findings to clinical nursing practice. *Journal of clinical nursing*, *26*(5-6), 862–872. https://doi.org/10.1111/jocn.13586

[5] Department of Health, Education, and Welfare, & National Commission for the Protection of Human Subjects of Biomedical and Behavioral Research (2014). The Belmont Report. Ethical principles and guidelines for the protection of human subjects of research. *The Journal of the American College of Dentists*, *81*(3), 4–13.

[6] Duma, N., Vera Aguilera, J., Paludo, J., Haddox, C. L., Gonzalez Velez, M., Wang, Y., Leventakos, K., Hubbard, J. M., Mansfield, A. S., Go, R. S., & Adjei, A. A. (2018). Representation of Minorities and Women in Oncology Clinical Trials: Review of the Past 14 Years. *Journal of oncology practice*, *14*(1), e1–e10. https://doi.org/10.1200/JOP.2017.025288

[7] Emanuel, E. J., Wendler, D., & Grady, C. (2000). What makes clinical research ethical?. *JAMA*, *283*(20), 2701–2711. https://doi.org/10.1001/jama.283.20.2701

[8] Emanuel, E. J., Wendler, D., Killen, J., & Grady, C. (2004). What makes clinical research in developing countries ethical? The benchmarks of ethical research. *The Journal of infectious diseases*, *189*(5), 930–937. https://doi.org/10.1086/381709

[9] Esnaola NF, Ford ME. Racial differences and disparities in cancer care and outcomes: where's the rub? Surg Oncol Clin N Am. 2012 Jul;21(3):417-37, viii. doi: 10.1016/j.soc.2012.03.012. PMID: 22583991; PMCID: PMC4180671.

[10] Faust, A., Sierawska, A., Krüger, K., Wisgalla, A., Hasford, J., & Strech, D. (2021). Challenges and proposed solutions in making clinical research on COVID-19 ethical: a status quo analysis across German research ethics committees. *BMC medical ethics*, *22*, 1-11.

[11] Fisher, J. A., & Kalbaugh, C. A. (2011). Challenging assumptions about minority participation in US clinical research. *American journal of public health*, *101*(12), 2217–2222. https://doi.org/10.2105/AJPH.2011.300279

[12] George, S., Duran, N., & Norris, K. (2014). A systematic review of barriers and facilitators to minority research participation among African Americans, Latinos, Asian Americans, and Pacific Islanders. *American journal of public health*, *104*(2), e16–e31. https://doi.org/10.2105/AJPH.2013.301706

[13] Hussain-Gambles, M., Atkin, K., & Leese, B. (2004). Why ethnic minority groups are under-represented in clinical trials: a review of the literature. *Health & social care in the community*, *12*(5), 382–388. https://doi.org/10.1111/j.1365-2524.2004.00507.x

[14] Kelsey MD, Patrick-Lake B, Abdulai R, Broedl UC, Brown A, Cohn E, Curtis LH, Komelasky C, Mbagwu M, Mensah GA, Mentz RJ, Nyaku A, Omokaro SO, Sewards J, Whitlock K, Zhang X, Bloomfield GS. Inclusion and diversity in clinical trials: Actionable steps to drive lasting change. Contemp Clin Trials. 2022 May;116:106740. doi: 10.1016/j.cct.2022.106740. Epub 2022 Mar 29. PMID: 35364292; PMCID: PMC9133187.

[15] Kobayashi, L. C., Wardle, J., & von Wagner, C. (2014). Limited health literacy is a barrier to colorectal cancer screening in England: evidence from the English Longitudinal Study of Ageing. *Preventive medicine*, *61*(100), 100–105. https://doi.org/10.1016/j.ypmed.2013.11.012

[16] Lipkus IM, Peters E. Understanding the role of numeracy in health: proposed theoretical framework and practical insights. Health Educ Behav. 2009 Dec;36(6):1065-81. doi: 10.1177/1090198109341533. Epub 2009 Oct 15. PMID: 19834054; PMCID: PMC2783983.

[17] National Center for Health Statistics (US). (2019). *Health, United States, 2018*. National Center for Health Statistics (US).

[18] Rosenberger, W. F., & Lachin, J. M. (2015). *Randomization in clinical trials: theory and practice*. John Wiley & Sons.

[19] Salmanu, R. A., Oluwatosin, O. A., Oladejo, A. D., Ede, N. A., Ayiloge, E., Jimoh, E. Z., & Adekoya, G. O. (2023). Pattern of healthcare service utilization among residents of a semi-urban community in Ibadan, Nigeria. *African Journal of Biomedical Research, 26*(3), 369–375. https://doi.org/10.4314/ajbr.v26i3.xxx

[20] Shavers, V. L., Lynch, C. F., & Burmeister, L. F. (2001). Factors that influence African-Americans' willingness to participate in medical research studies. *Cancer, 91*(1 Suppl), 233–236. https://doi.org/10.1002/1097-0142(20010101)91:1+<233::aid-cncr10>3.0.co;2-8

[21] Singh, H., Dange, K., Gujarathi, R. H., Loganathan, S., Bhuyan, D., & Jani, H. (2024). Discovering the impact of dietary interventions on gut microbiome and human health: The clinical trial perspective. *Journal of Applied Bioanalysis, 10*(2), 28–36. https://doi.org/10.53555/jab.v10i2.158

[22] Unger, J. M., Cook, E., Tai, E., & Bleyer, A. (2016). The Role of Clinical Trial Participation in Cancer Research: Barriers, Evidence, and Strategies. *American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting, 35*, 185–198. https://doi.org/10.1200/EDBK_156686

[23] Unger, J. M., Cook, E., Tai, E., & Bleyer, A. (2016). The Role of Clinical Trial Participation in Cancer Research: Barriers, Evidence, and Strategies. *American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting, 35*, 185–198. https://doi.org/10.1200/EDBK_156686

[24] World Medical Association (2013). World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects. *JAMA, 310*(20), 2191–2194. https://doi.org/10.1001/jama.2013.281053